NasdaqGS:MRNABiotechs
New Flu and RSV mRNA Data Might Change The Case For Investing In Moderna (MRNA)
In recent weeks, Moderna has shared late-breaking clinical data on its investigational flu vaccine mRNA-1010 and RSV vaccine mRESVIA, while presenting its mRNA and lipid nanoparticle innovations at major industry conferences in Washington and Boston.
These updates point to a broadening respiratory vaccine portfolio and deepening mRNA platform capabilities, which could influence how investors view the company’s pipeline depth and long-term positioning in vaccines and therapeutics.
Next, we’ll...